# A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

> **NCT05557591** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** BNT116
- **DRUG:** Cemiplimab

## Key facts

- **NCT ID:** NCT05557591
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-21
- **Primary completion:** 2028-01-26
- **Final completion:** 2028-05-16
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05557591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05557591, "A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05557591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*